HSBC Initiates Coverage On Regeneron Pharmaceuticals with Buy Rating, Announces Price Target of $890

Benzinga · 11/24/2025 11:10
HSBC analyst Yifeng Liu initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy rating and announces Price Target of $890.